- $369.54m
- $469.59m
- $130.19m
- 18
- 34
- 12
- 10
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 5.22 | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 2.84 | ||
| EV to EBITDA | 71.39 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -1.92% | ||
| Return on Equity | -49.64% | ||
| Operating Margin | -3.87% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 51.16 | 48.87 | 72.48 | 88.59 | 130.19 | 184.76 | 251.34 | 25.77% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | -74.62 | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Harrow, Inc. is an eyecare pharmaceutical company. The Company is engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the United States market. It provides a comprehensive portfolio of prescription and non-prescription pharmaceutical products. It owns commercial rights to portfolios of branded ophthalmic pharmaceutical products in North America, all of which are marketed under the Harrow name. It owns and operates ImprimisRx, an ophthalmology-focused pharmaceutical-compounding business. It owns United States commercial rights to various products: IHEEZO, VEVYE, TRIESENCE, VIGAMOX, ILEVRO, FLAREX, NATACYN, ZERVIATE and others. VIGAMOX (moxifloxacin hydrochloride ophthalmic solution) 0.5%, a fluoroquinolone antibiotic eye drops for the treatment of bacterial conjunctivitis caused by susceptible strains of organisms. IHEEZO (chloroprocaine hydrochloride ophthalmic gel) 3% is a low-viscosity gel indicated for ocular surface anesthesia.
Directors
- Mark Baum CHM (48)
- Andrew Boll CFO (38)
- John Saharek CEX (61)
- Larry Dillaha OTH
- Richard Lindstrom DRC (73)
- Robert Kammer IND (71)
- Teresa Sparks IND (52)
- R. Lawrence Van Horn IND (53)
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- January 11th, 2006
- Public Since
- February 8th, 2013
- No. of Shareholders
- 67
- No. of Employees
- 315
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
NASDAQ Global Market- Shares in Issue
- 35,362,642
- Address
- 102 WOODMONT BLVD, SUITE 610, NASHVILLE, 37215
- Web
- https://www.harrow.com/
- Phone
- +1 6157334731
- Auditors
- KMJ Corbin & Company LLP
Upcoming Events for HROW
Harrow Inc Annual Shareholders Meeting
Q2 2024 Harrow Inc Earnings Release
Similar to HROW
111
NASDAQ Global Market
ADMA Biologics
NASDAQ Global Market
Alimera Sciences
NASDAQ Global Market
ANI Pharmaceuticals
NASDAQ Global Market
Aquestive Therapeutics
NASDAQ Global Market
FAQ
What is the Harrow share price?
As of Today at 19:10 UTC, shares in Harrow are trading at $10.45. This share price information is delayed by 15 minutes.
How has the Harrow share price performed this year?
Shares in Harrow last closed at $10.45 and the price had moved by -56.09% over the past 365 days. In terms of relative price strength the Harrow share price has underperformed the S&P500 Index by -63.46% over the past year.
What are the analyst and broker recommendations for Harrow?
The overall consensus recommendation for Harrow is Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the Harrow dividend yield?
Harrow does not currently pay a dividend.
Does Harrow pay a dividend?
Harrow does not currently pay a dividend.
When does Harrow next pay dividends?
Harrow does not currently pay a dividend.
How do I buy Harrow shares?
To buy shares in Harrow you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Harrow?
As of the previous close price of $10.45, shares in Harrow had a market capitalisation of $369.54m.
Where are Harrow shares listed?
Here are the trading details for Harrow:
- Country of listing: United States
- Exchange: NMQ
- Ticker Symbol: HROW
What kind of share is Harrow?
Based on an overall assessment of its quality, value and momentum Harrow is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Harrow share price forecast for 2024?
The analyst consensus target price for shares in Harrow is $25.65. That is 145.45% above the last closing price of $10.45.
Analysts covering Harrow currently have a consensus Earnings Per Share (EPS) forecast of -$0.32 for the next financial year.
What is the trend in the Harrow share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Harrow. Over the past six months, its share price has underperformed the S&P500 Index by -38.39%.
As of the last closing price of $10.45, shares in Harrow were trading -21.08% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Harrow PE Ratio?
The Harrow PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $10.45.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Harrow?
Harrow's management team is headed by:
- Mark Baum - CHM
- Andrew Boll - CFO
- John Saharek - CEX
- Larry Dillaha - OTH
- Richard Lindstrom - DRC
- Robert Kammer - IND
- Teresa Sparks - IND
- R. Lawrence Van Horn - IND